The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases
- 11 March 2010
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 149 (1), 3-13
- https://doi.org/10.1111/j.1365-2141.2010.08076.x
Abstract
Depletion of B lymphocytes using the anti-CD20 monoclonal antibody rituximab has wide-spread use in the treatment of patients with autoimmune disorders. As haematopoietic progenitor cells and only a fraction of differentiated plasma express CD20, the effect of rituximab on immune function appears to be minimal. However, hypogammagobulinaemia can occur with repeated doses and emerging data from large studies suggest a subtle increase in the risk of infection. Reactivation of latent JC virus, resulting in progressive multifocal leucoencephalopathy, and hepatitis B virus, resulting in hepatoxicity, have been documented in patients receiving rituximab; although confounding effects of concomitant immunosuppressive therapies and immune dysregulation due to the underlying disease make causal associations of infections problematic. This review discusses the efficacy of B cell depletion therapy in the treatment of autoimmune diseases, the effect of B cell depletion on infection and immunity including the role of the B cell in autoimmunity, and identifies areas of controversy.Keywords
This publication has 100 references indexed in Scilit:
- Activating systemic autoimmunity: B's, T's, and tollsCurrent Opinion in Immunology, 2009
- Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports projectBlood, 2009
- Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS)Pediatric Blood & Cancer, 2009
- Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without RituximabJournal of Clinical Oncology, 2009
- Frequency of Regulatory T Cells is Not Affected by Transient B Cell Depletion Using Anti-CD20 Antibodies in Rheumatoid ArthritisThe Open Rheumatology Journal, 2009
- Therapeutic B cell depletion impairs adaptive and autoreactive CD4+T cell activation in miceProceedings of the National Academy of Sciences of the United States of America, 2007
- Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in miceJCI Insight, 2007
- T cell–dependent survival of CD20+ and CD20− plasma cells in human secondary lymphoid tissueBlood, 2007
- Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptorsSeminars in Immunology, 2007
- Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous systemAnnals Of The Rheumatic Diseases, 2006